{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=amikacin&page=2",
    "query": {
      "intervention": "amikacin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=amikacin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T10:27:28.360Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04677569",
      "title": "Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mycobacterium Infections, Nontuberculous"
      ],
      "interventions": [
        {
          "name": "ALIS",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol",
          "type": "DRUG"
        },
        {
          "name": "ELC (matching placebo for ALIS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 425,
      "start_date": "2021-04-01",
      "completion_date": "2026-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 90,
      "location_summary": "Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04677569"
    },
    {
      "nct_id": "NCT00775138",
      "title": "Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "280 mg Arikayce™",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "560 mg Arikayce™",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Cohort 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2008-06-24",
      "completion_date": "2009-05-11",
      "has_results": true,
      "last_update_posted_date": "2019-07-10",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00775138"
    },
    {
      "nct_id": "NCT01021436",
      "title": "Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "Amikacin inhalation solution (BAY41-6551)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-03",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2016-02-18",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 4,
      "location_summary": "Birminghan, Alabama • Cincinnati, Ohio • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Birminghan",
          "state": "Alabama"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01021436"
    },
    {
      "nct_id": "NCT05227937",
      "title": "Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Amikacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Antonios Likourezos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "110 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 110 Years · Female only"
      },
      "enrollment_count": 75,
      "start_date": "2022-09-21",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05227937"
    },
    {
      "nct_id": "NCT03038178",
      "title": "Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mycobacterium Infections, Nontuberculous",
        "Mycobacteria, Atypical"
      ],
      "interventions": [
        {
          "name": "LAI plus multi-drug regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kevin Winthrop",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2016-10",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Tyler, Texas",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038178"
    },
    {
      "nct_id": "NCT06418711",
      "title": "ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "MAC Lung Disease",
        "Treatment Refractory MAC Lung Disease",
        "Mycobacterium Infections, Nontuberculous"
      ],
      "interventions": [
        {
          "name": "Clofazimine Inhalation Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 132,
      "start_date": "2024-09-11",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06418711"
    },
    {
      "nct_id": "NCT02709265",
      "title": "Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "amikacin/fosfomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cardeas Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-04",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709265"
    },
    {
      "nct_id": "NCT00707239",
      "title": "Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia, Bacterial"
      ],
      "interventions": [
        {
          "name": "tigecycline",
          "type": "DRUG"
        },
        {
          "name": "imipenem/cilastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2008-12",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2012-07-10",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707239"
    },
    {
      "nct_id": "NCT00042289",
      "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "atazanavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "elvitegravir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "tenofovir alafenamide fumarate (TAF)",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat or ritonavir",
          "type": "DRUG"
        },
        {
          "name": "efavirenz",
          "type": "DRUG"
        },
        {
          "name": "darunavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir/tenofovir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        },
        {
          "name": "ethambutol",
          "type": "DRUG"
        },
        {
          "name": "isoniazid",
          "type": "DRUG"
        },
        {
          "name": "pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "kanamycin",
          "type": "DRUG"
        },
        {
          "name": "amikacin",
          "type": "DRUG"
        },
        {
          "name": "capreomycin",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "levoflaxacin",
          "type": "DRUG"
        },
        {
          "name": "ofloxacin",
          "type": "DRUG"
        },
        {
          "name": "ethionamide/prothionamide",
          "type": "DRUG"
        },
        {
          "name": "terizidone/cycloserine",
          "type": "DRUG"
        },
        {
          "name": "para-aminosalicylic acid (PAS)",
          "type": "DRUG"
        },
        {
          "name": "high dose INH",
          "type": "DRUG"
        },
        {
          "name": "bedaquiline",
          "type": "DRUG"
        },
        {
          "name": "clofazamine",
          "type": "DRUG"
        },
        {
          "name": "delamanid",
          "type": "DRUG"
        },
        {
          "name": "linezolid",
          "type": "DRUG"
        },
        {
          "name": "pretomanid",
          "type": "DRUG"
        },
        {
          "name": "ethinyl estradiol",
          "type": "DRUG"
        },
        {
          "name": "etonogestrel implant",
          "type": "DRUG"
        },
        {
          "name": "nevirapine",
          "type": "DRUG"
        },
        {
          "name": "amprenavir",
          "type": "DRUG"
        },
        {
          "name": "abacavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "fosamprenavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "didanosine delayed release (Videx® EC)",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "tenofovir",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "tipranavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #4",
          "type": "DRUG"
        },
        {
          "name": "raltegravir",
          "type": "DRUG"
        },
        {
          "name": "etravirine",
          "type": "DRUG"
        },
        {
          "name": "maraviroc",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "tenofovir/atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1578,
      "start_date": "2003-06-09",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042289"
    },
    {
      "nct_id": "NCT00035425",
      "title": "Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Febrile Neutropenia"
      ],
      "interventions": [
        {
          "name": "linezolid",
          "type": "DRUG"
        },
        {
          "name": "vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2001-11",
      "completion_date": "2002-11",
      "has_results": false,
      "last_update_posted_date": "2009-12-01",
      "last_synced_at": "2026-09-25T10:27:28.360Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035425"
    }
  ]
}